Health Affairs, 25, no. 5 (2006): 1249-1259 doi: 10.1377/hlthaff.25.5.1249 © 2006 by Project HOPE	New Online   House Health Reform Bill   Paying for Reform   Vetting AHIP's Report   HIV/AIDS Costs   Brief: Insurance Reform   HA Blog Top 10

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Cotter, D. Articles by Bullock, K. Search for Related Content PubMed PubMed Citation Articles by Cotter, D. Articles by Bullock, K. Related Collections Access To Care Insurance Coverage Managed Care - Medicare Medicare Business Of Health Pharmaceuticals Research And Technology Health Spending Consumer Issues Insurance Market Evidence-Based Medicine

Coverage

Translating Epoetin Research Into Practice: The Role Of Government And The Use Of Scientific Evidence

Spending for epoetin is Medicare’s single largest drug expenditure. We chronicle the evolution of epoetin policy based on a lack of well-designed post–Food and Drug Administration approval studies demonstrating clinical benefit; congressional/federal agency reliance on clinical practice guidelines that might have misinterpreted evidence supporting causality; and the premature translation of research into practice and policy. Were the right choices made? Epoetin showcases the risk and benefit conundrum created when evidentiary standards are relaxed. Our review concludes with broad-based policy recommendations for the newly implemented Medicare Part D program.

                      What's this?

This article has been cited by other articles:

				A. K. Singh Anemia of Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 3 - 6. [Full Text] [PDF]

				M. Thamer, Y. Zhang, J. Kaufman, D. Cotter, F. Dong, and M. A. Hernan Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving Hemodialysis JAMA, April 18, 2007; 297(15): 1667 - 1674. [Abstract] [Full Text] [PDF]

				H. S. Luft Universal Health Care Coverage: A Potential Hybrid Solution JAMA, March 14, 2007; 297(10): 1115 - 1118. [Full Text] [PDF]

				S. Shaldon Does erythropoetin improve survival in ESRD haemodialysis patients? Nephrol. Dial. Transplant., March 1, 2007; 22(3): 962 - 962. [Full Text] [PDF]

				S. Shaldon The use of IV iron in the treatment of anaemia of ESRD patients on maintenance haemodialysis: an historical and personal view Nephrol. Dial. Transplant., January 1, 2007; 22(1): 23 - 25. [Full Text] [PDF]